On Monday, Edgewise Therapeutics, Inc., (NASDAQ:EWTX) revealed topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy (BMD), is a genetic disorder that causes progressive muscle weakness. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induced damage in muscular dystrophies. Also Read: Edgewise Therapeutics Stock S…

Benzinga

New York

United States

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease - Edgewise Therapeutics (NASDAQ:EWTX)

Ad Fontes Media

Media Bias/Fact Check

Green Stock News for the New Green Economy.

Green Stock News

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Diseases of the muscles are numerous. Sadly, most of them are distressing, and in some cases life-threatening. Muscles literally hold our bodies together. They also move and support our organs. Weakness or the wasting away of muscle tissue can seriously inhibit mobility and our ability to breathe properly. Symptoms typically include aches, pains, and increasing disability. Deformity is not uncommon. And in the most extreme cases, a disease of th…

Stars Insider

Diseases that mess with muscles

Edgewise Therapeutics reports positive Phase 2 results for sevasemten in Becker muscular dystrophy, showing significant muscle protection and promising functional outcomes.

stocktitan.net

Edgewise's Muscular Dystrophy Drug Shows Promising 28% Reduction in Muscle Damage in Phase 2 Trial

New York, Dec.  16, 2024  (GLOBE NEWSWIRE) — The Muscular Dystrophy Association (MDA) announced today the awarding of 21 new grants with a total funding commitment of over $5 million toward neuromuscular disease research. These grants, recommended by MDA’s Research Advisory Committee, include 14 research grants and 7 development awards, and fund research across a wide spectrum of neuromuscular diseases, such as amyotrophic lateral sclerosis (ALS…

dailyguardian.ca

Muscular Dystrophy Association Announces Over $5 Million in Research Grants to Advance Neuromuscular Disease Research

Edgewise Therapeutics’ treatment candidate for several forms of muscular dystrophy has hit the primary endpoint in a mid-stage study, setting in motion plans for regulatory talks that could enable accelerated approval.

Endpoints News

Edgewise shares spike on Phase 2 success for muscular dystrophy drug

The biotech company will meet with regulators to discuss Phase 2 biomarker data that sent its shares climbing by more than 20% Monday.

biopharmadive.com

Edgewise weighs fast approval path for muscular dystrophy drug

The positive data, along with data from GRAND CANYON anticipated in early 2025, are thought to be part of a potential future authorization submission for sevasemten in Becker.

neurologylive.com

Sevasemten Meets Primary End Point in Phase 2 CANYON Trial of Becker Muscular Dystrophy

Sevasemten significantly reduced two markers of muscle damage in treated Becker muscular dystrophy patients in Phase 2 CANYON trial.

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease - Edgewise Therapeutics (NASDAQ:EWTX)

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics